AL Amyloidosis

6
Pipeline Programs
4
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 6 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Prothena
ProthenaDUBLIN 2, Ireland
4 programs
3
NEOD001Phase 21 trial
NEOD001Phase 21 trial
NEOD001Phase 21 trial
non-interventionalN/A1 trial
Active Trials
NCT02574676Completed343Est. Jul 2018
NCT02632786Completed129Est. Mar 2018
NCT02613182Terminated34Est. May 2018
+1 more trials
Bristol Myers Squibb
1 program
1
IsatuximabPhase 2Monoclonal Antibody
Genentech
GenentechCA - Oceanside
1 program
1
Venetoclax Oral Tablet, 200 mgPhase 1/21 trial
Active Trials
NCT05451771Recruiting53Est. Sep 2026
Oncopeptides
OncopeptidesSweden - Stockholm
1 program
1
Melphalan-FlufenamidePhase 11 trial
Active Trials
NCT04115956TerminatedEst. Jan 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ProthenaNEOD001
ProthenaNEOD001
ProthenaNEOD001
GenentechVenetoclax Oral Tablet, 200 mg
OncopeptidesMelphalan-Flufenamide
Prothenanon-interventional

Clinical Trials (6)

Total enrollment: 639 patients across 6 trials

NCT03154047ProthenaNEOD001

Study in Subjects With Light Chain (AL) Amyloidosis

Start: Jun 2017Est. completion: May 201880 patients
Phase 2Terminated
NCT02632786ProthenaNEOD001

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

Start: Mar 2016Est. completion: Mar 2018129 patients
Phase 2Completed
NCT02613182ProthenaNEOD001

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Start: Feb 2016Est. completion: May 201834 patients
Phase 2Terminated
NCT05451771GenentechVenetoclax Oral Tablet, 200 mg

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Start: Oct 2022Est. completion: Sep 202653 patients
Phase 1/2Recruiting
NCT04115956OncopeptidesMelphalan-Flufenamide

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Start: Aug 2020Est. completion: Jan 2022
Phase 1Terminated
NCT02574676Prothenanon-interventional

Quality of Life (QOL) Registry for Patients With AL Amyloidosis

Start: Oct 2015Est. completion: Jul 2018343 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 639 patients
4 companies competing in this space